Protection has, in fact, been achieved by administering polyclonal and monoclonal antiHIV-1 neutralizing antibodies (NAbs) to humanized mice or macaques prior to challenge with SIV/HIV chimeric viruses (SHIVs)1-8. During the past seven years, monoclonal antibodies (MAbs) have been isolated from selected HIV-1 infected individuals, who generate anti-viral NAbs (bNAbs) with broad and potent activity